CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Common Challenges Hampering Clinical Laboratory Services

Common Challenges Hampering Clinical...

Adherehealth and Levrx Technology Establish a Strategic Partnership to Improve Medication Optimization

Adherehealth and Levrx Technology...

Clinical Researchs Most Recent Developments

Clinical Researchs Most Recent...

Aceragen Receives Grant from Cystic Fibrosis Foundation to Advance Novel Therapy

Aceragen Receives Grant from Cystic...

Giuliano to Lead Finance-Related Leadership Functions as New CFO at Aeterna

Giuliano to Lead Finance-Related...

Top Ways Netsuite Transforms Life Science Industry for Good

Top Ways Netsuite Transforms Life...

Rain Therapeutics and Roche to Jointly Conduct Immunotherapy Trial Solid Tumor Treatment

Rain Therapeutics and Roche to...

4 Common Challenges in Clinical Trials - How Are You Addressing Them?

4 Common Challenges in Clinical...

Common Challenges Hampering Clinical Laboratory Services

Common Challenges Hampering Clinical...

Adherehealth and Levrx Technology Establish a Strategic Partnership to Improve Medication Optimization

Adherehealth and Levrx Technology...

Clinical Researchs Most Recent Developments

Clinical Researchs Most Recent...

Aceragen Receives Grant from Cystic Fibrosis Foundation to Advance Novel Therapy

Aceragen Receives Grant from Cystic...

Giuliano to Lead Finance-Related Leadership Functions as New CFO at Aeterna

Giuliano to Lead Finance-Related...

Top Ways Netsuite Transforms Life Science Industry for Good

Top Ways Netsuite Transforms Life...

Rain Therapeutics and Roche to Jointly Conduct Immunotherapy Trial Solid Tumor Treatment

Rain Therapeutics and Roche to...

4 Common Challenges in Clinical Trials - How Are You Addressing Them?

4 Common Challenges in Clinical...

China biopharma sector focuses on innovation.

Life Sciences Review | Wednesday, December 29, 2021
Tweet

Summary: China’s biopharma sector has seen a major shift from formerly generics-focused play to the one that encourages and concentrates on innovation, along with profound implications for patients and industry peers.


FREMONT, CA:A momentous shift from a formerly generics focused play into one that encourages innovation, along with profound implications for patients and industry peers has been experienced by China's biopharmaceutical ecosystem.Highlighted by substantial value creation on global capital markets, innovation in Chinese biopharma is close to becoming a notable story. The market value of publicly listed biopharma innovation players from China such as the Nasdaq, Shangai Stock Exchange Science and Technology Innovation Board (STAR) and Hong Kong Stock Exchange (HKEX) reached 380 billion dollars in July 2021, from 3 billion dollars in 2016.


Of the total, the China originated biotechnology companies independently have accounted for 180 billion dollars. Additionally, with 23 IPOs in the last year alone, the public debuts for Chinese players have also revived. Therefore, as seven out of the world's top ten largest biopharma IPOs have originated from China from 2018 to 2021, the Chinese biotechs are currently leading on IPO fundraising. 


Additionally, the rising demand for new drug discoveries with the potential to satisfy the domestic market needs and beyond has helped China increase its share of the global pipeline from 4.1 percent in 2015 to 13.9 percent in 2020.


Moreover, in enabling Chinese biopharma to emerge on the global innovation stage, regulatory reforms, the emergence of bioclusters in areas such as the city of Suzhou, the opening of China's capital markets, and the talent returning from overseas have played a vital role. McKinsey maintains the China Drug Innovation Index (CDII) in order to comprehend how China's biopharma innovation ecosystem is evolving and to obtain a more subtle sense regarding its growth drivers. This survey that was first launched in 2016 questions the industry experts to measure five dimensions that support healthy biopharma innovation such as policy environment which is split between regulatory reforms and market access policies, funding, research and development, local innovation output, and integration with global markets.


Weekly Brief

loading
Top 10 Clinical Trial Services Companies - 2022
Top 10 Emerging Clinical Trial Management Companies - 2022
Top 10 Clinical Trial Management System Companies - 2022
Top 10 Clinical Trial Services Companies - 2022
Top 10 Emerging Clinical Trial Management Companies - 2022
Top 10 Clinical Trial Management System Companies - 2022
> <
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue

Read Also

Role of Predictive Genomics in Sustainable Healthcare

Role of Predictive Genomics in Sustainable Healthcare

A Conversational AI Approach to Regulatory Intelligence

A Conversational AI Approach to Regulatory Intelligence

A rise in DNA Sequencing Market is expected in coming years

A rise in DNA Sequencing Market is expected in coming years

Omniabio Inc. Announces Private Investor

Omniabio Inc. Announces Private Investor
Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Lithuania's Vision to Become a Biotech Hub in Europe

Lithuania's Vision to Become a Biotech Hub in Europe

Bridging the Diversity Gap in Genomics

Bridging the Diversity Gap in Genomics

How does Biotechnology Provide Solutions to Human Needs?

How does Biotechnology Provide Solutions to Human Needs?
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/china-biopharma-sector-focuses-on-innovation-nwid-674.html